Benzathine benzylpenicillin


Full Generic Medicine Info
Dosage/Direction for Use

Intramuscular
Syphilis
Adult: Primary, secondary and latent: 1.8 g (2.4 MIU) as a single dose. Late (tertiary and neurosyphilis): 1.8 g (2.4 MIU) once wkly for 3 doses.

Intramuscular
Treponemal infections
Adult: 900 mg (1.2 MIU) as a single dose.
Child: 450 mg (600,000 U) as a single dose.

Intramuscular
Streptococcal pharyngitis
Adult: 900 mg (1.2 MIU) as a single dose.
Child: <27 kg: 225-450 mg (300,000-600,000 U) as a single dose; ≥27 kg: 675 mg (900,000 U) as a single dose.

Intramuscular
Congenital syphilis
Child: Normal CSF: <2 yr 37.5 mg/kg (50,000 U/kg) as a single dose;. 2-12 yr Adjust dosage based on adult dosage schedule.

Intramuscular
Primary prophylaxis of rheumatic fever
Adult: 900 mg (1.2 MIU) as a single dose. Prevention of recurrence of acute attack: 900 mg (1.2 MIU) once every 3 or 4 wk or 450 mg (600,000 U) once every 2 wk.
Child: <27 kg: 225-450 mg (300,000-600,000 U) as a single dose; ≥27 kg: 675 mg (900,000 U) as a single dose. Prevention of recurrence of acute attack: <27 kg: 450 mg (600,000 U) once every 3 or 4 wk; ≥27 kg: 900 mg (1.2 MIU) once every 3 or 4 wk.
Contraindications
Hypersensitivity to penicillins.
Special Precautions
Patient w/ previous hypersensitivity reactions to cephalosporins, history of allergy, asthma, seizure disorder. Not intended for IV or intra-arterial admin or inj near major peripheral nerves of blood vessels. Prolonged use may result in bacterial or fungal superinfection. Renal impairment. Monitoring Parameters Periodic evaluation of renal and haematopoietic functions. Assess culture and sensitivity test prior to initiation of therapy. Monitor for hypersensitivity reactions and opportunistic infections.
Adverse Reactions
Hypersensitivity reactions including skin eruptions, urticaria, laryngeal oedema, serum sickness-like reactions, allergic vasculitis, pruritus, fatigue, asthenia, pain, headache; fever; haemolytic anaemia, leucopenia, thrombocytopenia; neuropathy; nephropathy; hypotension, tachycardia, palpitations, pulmonary HTN, pulmonary embolism, vasodilation, vasovagal reaction, cerebrovascular accident, syncope; nausea, vomiting, intestinal necrosis, blood in stool, intestinal necrosis; lymphadenopathy; inj site reactions (e.g. pain, inflammation), joint disorder, periostitis, exacerbation of arthritis, myoglobinuria, rhabdomyolysis; nervousness, tremors, dizziness, somnolence, confusion, anxiety, euphoria, transverse myelitis, seizures, coma; hypoxia, apnoea, dyspnoea; diaphoresis; blurred vision, blindness; neurogenic bladder, haematuria, proteinuria, renal failure, impotence, priapism.
Potentially Fatal: Anaphylaxis, antibiotic-associated pseudomembranous colitis.
Drug Interactions
Bactericidal effect may be antagonised by tetracycline. Decreased rate of excretion and increased serum concentration when used w/ probenecid.
Lab Interference
May cause false-positive result in urinary and/or serum protein test, false positive or negative result for glycosuria test using copper sulfate reagent method, positive Coombs' test.
Action
Benzathine benzylpenicillin interferes w/ bacterial cell wall synthesis during active multiplication causing cell wall death and resultant bactericidal activity against susceptible bacteria.
Duration: 1-4 wk.
Absorption: Slowly absorbed from the site of inj. Time to peak plasma concentration: W/in 12-24 hr.
Distribution: Distributed throughout body tissues; CSF (minimal amount). Plasma protein binding: Approx 60%.
Metabolism: Hydrolysed to benzylpenicillin.
Excretion: Via urine.
Storage
Intramuscular: Store between 2-8°C. Do not freeze.
CIMS Class
ATC Classification
J01CE08 - benzathine benzylpenicillin ; Belongs to the class of beta-lactamase sensitive penicillins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on benzathine benzylpenicillin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in